Wuhan Hiteck Biological Pharma Co Ltd
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Epramine for injection; mouse nerve growth factor for injection; Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy fo… Read more
Market Cap & Net Worth: Wuhan Hiteck Biological Pharma Co Ltd (300683)
Wuhan Hiteck Biological Pharma Co Ltd (SHE:300683) has a market capitalization of $620.29 Million (CN¥4.55 Billion) as of March 18, 2026. Listed on the SHE stock exchange, this China-based company holds position #12100 globally and #2955 in its home market, demonstrating a 1.96% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Wuhan Hiteck Biological Pharma Co Ltd's stock price CN¥34.77 by its total outstanding shares 130894391 (130.89 Million).
Wuhan Hiteck Biological Pharma Co Ltd Market Cap History: 2017 to 2026
Wuhan Hiteck Biological Pharma Co Ltd's market capitalization history from 2017 to 2026. Data shows change from $957.84 Million to $620.29 Million (-3.35% CAGR).
Wuhan Hiteck Biological Pharma Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Wuhan Hiteck Biological Pharma Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.66x
Wuhan Hiteck Biological Pharma Co Ltd's market cap is 0.66 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $957.84 Million | $750.26 Million | $142.39 Million | 1.28x | 6.73x |
| 2018 | $481.34 Million | $590.87 Million | $94.14 Million | 0.81x | 5.11x |
| 2019 | $535.21 Million | $620.16 Million | $63.04 Million | 0.86x | 8.49x |
| 2020 | $729.29 Million | $524.12 Million | -$25.03 Million | 1.39x | N/A |
| 2021 | $1.06 Billion | $614.68 Million | $27.65 Million | 1.73x | 38.42x |
| 2022 | $631.53 Million | $688.63 Million | -$14.03 Million | 0.92x | N/A |
| 2023 | $644.19 Million | $602.28 Million | -$120.82 Million | 1.07x | N/A |
| 2024 | $425.30 Million | $648.97 Million | -$69.35 Million | 0.66x | N/A |
Competitor Companies of 300683 by Market Capitalization
Companies near Wuhan Hiteck Biological Pharma Co Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Wuhan Hiteck Biological Pharma Co Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Wuhan Hiteck Biological Pharma Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Wuhan Hiteck Biological Pharma Co Ltd's market cap moved from $957.84 Million to $ 620.29 Million, with a yearly change of -3.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥620.29 Million | +25.39% |
| 2025 | CN¥494.70 Million | +16.32% |
| 2024 | CN¥425.30 Million | -33.98% |
| 2023 | CN¥644.19 Million | +2.01% |
| 2022 | CN¥631.53 Million | -40.56% |
| 2021 | CN¥1.06 Billion | +45.69% |
| 2020 | CN¥729.29 Million | +36.26% |
| 2019 | CN¥535.21 Million | +11.19% |
| 2018 | CN¥481.34 Million | -49.75% |
| 2017 | CN¥957.84 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Wuhan Hiteck Biological Pharma Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $620.29 Million USD |
| MoneyControl | $620.29 Million USD |
| MarketWatch | $620.29 Million USD |
| marketcap.company | $620.29 Million USD |
| Reuters | $620.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.